查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1197326

顱內動脈瘤市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Intracranial Aneurysm Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，顱內動脈瘤市場預計將以 4.5% 的複合年增長率登記。

COVID-19 大流行通過直接影響需求和生產、擾亂供應鏈並增加公司的財務負擔，嚴重影響了顱內動脈瘤市場。. 在此期間，腦部手術也被推遲或取消，以遏制病毒的傳播。 受災最嚴重的國家，包括美國、俄羅斯、印度、巴西、法國、英國、意大利和西班牙，神經外科手術減少了 55%。 然而，根據基準年 1 月發表的“COVID-19 和醫院評論”，高達 36% 的住院 COVID-19 患者出現神經系統症狀，伴有少量缺血性和出血性梗死。已經發生。 這些結果表明 COVID-19 可能會提高神經行業的銷售額。 因此，這些因素為市場在短時間內的增長創造了有利可圖的機會，並為 COVID-19 後的主要參與者提供了有利可圖的機會。

患有高血壓和血管外傷的患者增加也是推動顱內動脈瘤市場的因素之一。 高血壓會顯著增加腦動脈瘤的風險。 由於高血壓和吸煙，很大一部分人口有患腦動脈瘤的風險。 根據世衛組織基準年更新，全球估計有 12.8 億 30-79 歲的成年人患有高血壓，其中大多數（三分之二）生活在低收入和中等收入國家。 我們推測這種趨勢將在預測期內持續，導致顱內動脈瘤。 因此，未來市場有望大幅增長。 此外，全球人口老齡化正在加速。

此外，根據基準年 10 月發表的“老年患者未破裂腦動脈瘤：主要挑戰和管理”研究，據說老年人未破裂腦動脈瘤的患病率正在迅速增加。 根據世界人口展望，世界 65 歲及以上人口的比例預計將從今年的 10% 上升到 2050 年的 16%。 到 2050 年，全球 65 歲及以上人口的數量將是 5 歲以下兒童數量的兩倍以上，幾乎與 12 歲以下兒童數量持平。 因此，隨著老年人口的增加，顱內動脈瘤的數量預計會增加。 預計市場在預測期內將出現更好的增長。

製造商為滿足對創新產品不斷增長的需求而增加產品推出，預計將推動市場增長。 例如，印度美敦力於今年6月推出了具有Conformite Europeenne（CE）標誌的第4代腦動脈瘤血管內治療分流器“Pipeline Vantage with Shield Technology”。 此外，2022 年 2 月，Viz.ai 軟件獲得了美國食品和藥物管理局的許可，可以自動檢測腦動脈瘤。 這些因素可能會推動全球對顱內動脈瘤治療的需求。

然而，高昂的治療費用預計會阻礙顱內動脈瘤市場的增長。

顱內動脈瘤市場趨勢

顱內動脈瘤市場，血管內栓塞事業部有望佔據較大份額

預計未來血管內彈簧圈會有健康的發展。 它是一種微創技術，使用導管治療腦動脈瘤並阻止血液流入動脈。 與這種治療相關的優勢，例如容易進入椎基底動脈系統、遠處有多個動脈瘤，以及與其他治療相比恢復時間更短，正在推動這一領域的增長。

此外，全球中風發病率不斷上升，這可能會導致血管破裂導致顱內動脈瘤，這也推動了市場收入的增長。

例如，根據世界中風組織 (WSO) 於 2022 年發布的數據，大約有 1200 萬人 (12,224,551) 經歷過中風。 該組織表示，每年有超過 1220 萬例新中風，在全球範圍內，25 歲以上的人中有四分之一在其一生中會經歷中風。 因此，全球中風患者負擔的增加預計將推動市場增長。

此外，預計主要參與者增加產品發布將提振市場。 例如，2022 年 6 月，Rapid Medical 宣布擴大其在美國的產品組合和首個 Numen 彈簧圈栓塞術。 Rapid Medical 與 MicroPort Scientific Corporation 的子公司 MicroPort NeuroTech 簽訂了獨家經銷協議。 因此，預計產品發布將在預測期內推動該細分市場的增長。

因此，上述所有因素都有望在預測期內提振該細分市場。

北美佔據了很大的市場份額，預計在預測期內也會如此

由於人口老齡化加劇、顱內動脈瘤患病率增加、對微創手術的需求增加以及高血壓和中風的發病率，預計北美在顱內動脈瘤市場中佔有很大的市場份額。

中風是一種出現症狀後需要盡快治療的疾病。 因此，快速治療的可用性是美國高存活率的重要因素。 根據疾病預防控制中心 2022 年 4 月發布的數據，超過 795,000 名美國人中風。 其中，已知每年發生 610,000 例新病例。 統計數據顯示，中風是美國主要的死亡原因之一，在美國每 40 秒就有一人罹患中風。 隨著中風患者數量的增加，對其治療的需求也在增加，預計將推動顱內動脈瘤市場。

由於創新療法的開發、行業參與者的本地擴張以及新療法的進入，預計北美在預測期內將保持類似的主導地位。 2022 年 9 月，Vesalio 宣布美國食品藥品監督管理局 (FDA) 批准 NeVa VS 用於治療動脈瘤破裂後的腦血管痙攣。

因此，上述所有因素都有望在預測期內提振市場。

顱內動脈瘤市場競爭者分析

顱內動脈瘤市場競爭適中，由幾家大型企業組成。 目前主導市場的公司包括 Stryker、B. Braun Melsungen AG、MicroPort Scientific Corporation、Medtronic、Terumo Corporation、Integra LifeSciences Corporation、Johnson & Johnson 和 RAUMEDIC AG。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 對微創手術的需求不斷增加
    • 腦動脈瘤患病率上升
    • 技術進步
  • 市場製約因素
    • 高昂的治療費用
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按類型
    • 血管內彈簧圈
    • 手術剪報
    • 分流器
    • 其他類型
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 其他最終用戶
  • 按地區細分
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Stryker
    • B. Braun Melsungen AG
    • MicroPort Scientific Corporation
    • Medtronic
    • Terumo Corporation
    • Integra LifeSciences Corporation
    • Johnson & Johnson
    • RAUMEDIC AG
    • Microvention Inc.
    • Codman Neuro（Integra Lifesciences）

第7章 市場機會今後動向

簡介目錄
Product Code: 71255

The intracranial aneurysm market is expected to register a CAGR of 4.5% during the forecast period.

The COVID-19 pandemic severely impacted the market for intracranial aneurysms by directly affecting demand and production, disrupting the supply chain, and increasing the financial burden on firms. Brain surgeries were postponed or even canceled during this timeframe to reduce the spread of the virus. In worst-affected nations, such as the United States, Russia, India, Brazil, France, the United Kingdom, Italy, and Spain, neurosurgical operations fell by 55%. However, according to a study published in January of the base year titled "COVID-19 and Hospital: A review," up to 36% of hospitalized COVID-19 patients experienced neurological symptoms, and there were several ischemic and hemorrhagic infarctions. These findings suggested COVID-19 may enhance sales in the neurology industry. Thus, these factors created lucrative opportunities for the market to grow shortly, providing profitable opportunities for key players post-COVID-19.

The increasing number of patients suffering from high blood pressure and trauma to blood vessels is another factor driving the market for intracranial aneurysms. Hypertension significantly increases the risk of a brain aneurysm and other diseases. A large percentage of the population is at risk of developing brain aneurysms due to high blood pressure and smoking. As per the WHO updates from the base year, an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, with most (two-thirds) living in low- and middle-income countries. It is estimated that this trend will continue to rise even in the forecast period and lead to intracranial aneurysms. Thus, the market is expected to experience substantial growth in the future. In addition, the global population is aging at an accelerating pace.

Moreover, according to a study published in October of the base year titled "Unruptured Cerebral Aneurysms in Elderly Patients: Key Challenges and Management," the prevalence of unruptured brain aneurysms in elderly patients was rapidly increasing in patients aged 70 years or older. According to the World Population Prospects, this year, the share of the global population aged 65 years or above is projected to rise from 10% to 16% in 2050. By 2050, the number of people aged 65 years or over worldwide is projected to be more than twice the number of children under age five and about the same as that of children under age 12. Therefore, with the increase in the elderly population, intracranial aneurysms are expected to increase. The market is expected to show better growth over the forecast period.

The increasing launches by manufacturers to meet the growing demand for innovative products are expected to drive the market's growth. For instance, in June this year, India Medtronic launched Conformite Europeenne (CE) marked fourth-generation flow diverter, Pipeline Vantage with Shield Technology, for endovascular treatment of brain aneurysms. Moreover, in February 2022, Viz.ai software received United States Food and Drug Administration clearance for automatically spotting brain aneurysms. Such factors potentially drive the demand to adopt intracranial aneurysm treatments worldwide.

However, the high cost of treatment is expected to hamper the growth of the intracranial aneurysm market.

Intracranial Aneurysm Market Trends

Endovascular Coiling Segment is Expected to Hold a Significant Share in the Intracranial Aneurysm Market

Endovascular coiling is estimated to witness healthy growth in the future. It is a minimally invasive technique wherein a catheter is used to treat the brain aneurysm by preventing blood from getting into arteries. Benefits associated with this procedure, such as easy access to the vertebrobasilar system, multiple aneurysms in distant areas, and shorter recovery time compared to other procedures, propelling the segment's growth.

In addition, the growing number of strokes worldwide has a high chance of rupturing blood vessels and leading to intracranial aneurysms, thus promoting revenue growth in the market.

For instance, according to data published by World Stroke Organization (WSO) in 2022, About 12 million (12,224,551) people experienced a stroke. The organization stated that there are more than 12.2 million new strokes each year, and globally, one in four people after 25 years of age experience a stroke in their lifetime. Hence, the increasing burden of patients with stroke globally is expected to drive the market's growth.

Moreover, increasing product launches by key players are expected to boost the market. For instance, in June 2022, Rapid Medical announced the expansion of its portfolio in the United States and the first Numen coil embolization procedure. Rapid Medical has an exclusive distribution agreement with MicroPort NeuroTech, a subsidiary of MicroPort Scientific Corporation. Thus, product launches are expected to boost the market segment's growth over the forecast period.

Thus, all factors mentioned above are expected to boost the segment over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the intracranial aneurysm market due to the increasing aging population, increasing prevalence of intracranial aneurysms, rising demand for minimally invasive procedures, and incidences of hypertension and stroke.

Stroke is a condition where treatment must be given as early as possible after the onset of symptoms. Hence, the availability of quick treatment is a key factor responsible for the high survival rate in the United States. According to the statistics published by the CDC in April 2022, more than 795,000 Americans have strokes. Of this, 610,000 are found to be new cases each year. Statistics revealed stroke is one of the causes of death in the United States; every 40 seconds, people from the United States have a stroke. The increasing number of patients suffering from stroke is expected to increase the demand for its treatment, driving the market for intracranial aneurysms.

North America is expected to observe the same dominance during the forecast period due to the development of innovative therapies, major industry players' local presence, and new therapies' entry. In September 2022, Vesalio announced the Food and Drug Administration's approval of the NeVa VS to treat cerebral vasospasm after aneurysmal rupture.

Thus, all factors above are expected to boost the market over the forecast period.

Intracranial Aneurysm Market Competitor Analysis

The intracranial aneurysm market is moderately competitive and consists of several major players. Some companies currently dominating the market are Stryker, B. Braun Melsungen AG, MicroPort Scientific Corporation, Medtronic, Terumo Corporation, Integra LifeSciences Corporation, Johnson & Johnson, and RAUMEDIC AG.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand of Minimally Invasive Procedures
    • 4.2.2 Rising Prevalence of Brain Aneurysm
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Treatment
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type
    • 5.1.1 Endovascular Coiling
    • 5.1.2 Surgical Clipping
    • 5.1.3 Flow Diverters
    • 5.1.4 Other Types
  • 5.2 By End-user
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centers
    • 5.2.3 Other End-users
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Stryker
    • 6.1.2 B. Braun Melsungen AG
    • 6.1.3 MicroPort Scientific Corporation
    • 6.1.4 Medtronic
    • 6.1.5 Terumo Corporation
    • 6.1.6 Integra LifeSciences Corporation
    • 6.1.7 Johnson & Johnson
    • 6.1.8 RAUMEDIC AG
    • 6.1.9 Microvention Inc.
    • 6.1.10 Codman Neuro (Integra Lifesciences)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS